Loading quotes...
Forecast
The analysts' average price target is âŹ45.96 (-22.43%). The median is âŹ43.09 (-27.27%).
| Buy |
Â
10 |
| Hold |
Â
11 |
| Sell |
Â
1 |
News Go to news feed
10x Genomics reaches 52-week high at $66.95
Shares of 10x Genomics climbed to a 52-week high of $66.95, giving it a market capitalization of $8.71 billion. InvestingPro rates the stock as overvalued relative to its fair value, while the annual return was about 385.93 percent. In Q2 2026, 10x Genomics beat revenue and earnings forecasts but issued a muted outlook due to the transition to the new Atera platform. Analysts reacted mixedly: Stifel reiterated a buy rating, RBC assigned a âSector Performâ rating, and Canaccord raised the price target to $60. » More on de.investing.com
ARK-Investments buys Perceptive Capital and cuts 10X Genomics position
Cathie Woodâled ARK ETFs reported trades on August 14, 2026: the largest sale was 10,951 shares of 10X Genomics worth about $636,800, part of an ongoing reduction of the position. At the same time ARK bought 45,010 shares of Perceptive Capital Solutions for roughly $522,566 and increased holdings in Cerus and Schrödinger. Shares of the 3iQ Solana Staking ETF were also added, and smaller sales of Twist Bioscience and Brera Holdings were made. Overall, the transactions reflect a strategic portfolio reshuffle. » More on de.investing.com
10x Genomics stock reaches 52-week high at $50.36
10x Genomics shares rose to a new 52-week high of $50.36 after gaining 307.97% year-to-date and delivering a total return of 256% over the past twelve months. For Q2 2026 the company reported revenue of $151.04 million and an adjusted loss per share of $0.14, both better than expected. Despite the results, the stock fell after the announcement due to a more cautious near-term outlook and the transition to the new Atera platform. Data from InvestingPro suggest the stock is trading above its fair value, which is relevant for investors considering entry. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 132.34m | 9.79% |
| Gross profit | 98.57m | 7.12% |
| Net profit | -15.71m | 153.62% |
| EBITDA | -16.34m | 141.28% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ7.36bn |
Number of shares | 126.96m |
52-week high/low | âŹ58.28 - âŹ9.62 |
| Dividends | No |
Beta | 2.08 |
P/E ratio | -114.05 |
PEG ratio | 0.25 |
P/B ratio | 10.59 |
P/S ratio | 13.85 |
Company profile
10x Genomics, Inc. ist ein biowissenschaftliches Technologieunternehmen, das Instrumente, Verbrauchsmaterialien und Software fĂŒr die Analyse biologischer Systeme in Nordamerika, Europa, dem Nahen Osten, Afrika, China und im asiatisch-pazifischen Raum entwickelt und vertreibt. Das Unternehmen bietet Chrom- und Chrom-Connect-Instrumente, mikrofluidische Chips, ObjekttrĂ€ger, Reagenzien und andere Verbrauchsprodukte an. Zu den Einzelzelllösungen des Unternehmens, die auf den Chromium-Instrumenten laufen, gehören die Einzelzell-Genexpression zur Messung der GenaktivitĂ€t auf Zellbasis, das Einzelzell-Immunprofiling zur Messung der AktivitĂ€t von Immunzellen und ihrer Ziele, der Einzelzell-Assay fĂŒr Transposase Accessible Chromati (ATAC) zur Messung der Epigenetik, der die physikalische Organisation der DNA umfasst, und der Einzelzell-Multiome-ATAC + Genexpression zur Messung der genetischen AktivitĂ€t und der epigenetischen Programmierung in denselben Zellen ĂŒber Zehntausende von Zellen in einem einzigen Experiment. Das Unternehmen bietet auch die rĂ€umliche Genexpressionslösung Visium an, mit der rĂ€umliche Genexpressionsmuster in einer einzigen Gewebeprobe gemessen werden können oder die Genexpression und Proteinko-Detektion in Kombination mit Immunfluoreszenz. Das Unternehmen beliefert verschiedene akademische, staatliche, biopharmazeutische, biotechnologische und andere Einrichtungen. Das Unternehmen war frĂŒher als 10X Technologies, Inc. bekannt und Ă€nderte im November 2014 seinen Namen in 10x Genomics, Inc. um. 10x Genomics, Inc. wurde im Jahr 2012 gegrĂŒndet und hat seinen Hauptsitz in Pleasanton, Kalifornien.
| Name | 10X Genomics |
| CEO | Serge Saxonov |
| Headquarters | Pleasanton,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 12/09/2019 |
| Employees | 1,178 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TXG |
Frankfurt | 1KJ.F |
DĂŒsseldorf | 1KJ.DU |
London | 0A88.L |
MĂŒnchen | 1KJ.MU |